Irish biopharmaceutical company Inflazome announced that it has landed an additional $63 million in Series B financing round.
Inflazome will use the net proceeds for its small-molecule inhibitors of cryopyrin inflammasome advancements into multiple clinical trials in 2019.
Led by Dutch life sciences venture capital firm Forbion, the round also had participation from U.S.-based Longitude Capital and founding investors Swiss peer Novartis Venture Fund and Fountain Healthcare Partners.
The latest round brings the total capital raised by Inflazome to more than $700 million.